- Trials with a EudraCT protocol (637)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
637 result(s) found.
Displaying page 1 of 32.
EudraCT Number: 2010-019252-41 | Sponsor Protocol Number: 242187 | Start Date*: 2011-08-03 | |||||||||||
Sponsor Name:VU University Medical Center | |||||||||||||
Full Title: DALI dosing study of Vitamin D in obese pregnant women | |||||||||||||
Medical condition: Gestational diabetes | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: AT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-003549-16 | Sponsor Protocol Number: Tulir 03/01 | Start Date*: 2006-03-08 | |||||||||||
Sponsor Name:NeuroBiotec GmbH | |||||||||||||
Full Title: Transdermal Lisuride: A double-blind, randomized, active- and placebo-controlled multi-centre phase III efficacy trial for the treatment of patients with Restless Legs Syndrome (RLS) | |||||||||||||
Medical condition: Idiopathic and Uremic Restless Legs Syndrome (RLS) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-000648-15 | Sponsor Protocol Number: BH4/III/05/001 | Start Date*: 2006-06-08 | |||||||||||
Sponsor Name:ORPHANETICS Pharma Entwicklungs- GmbH | |||||||||||||
Full Title: A double-blind, placebo-controlled, multicentre study with an open-label extension to evaluate the efficacy and safety of tetrahydrobiopterin (BH4) in children and adolescents with hyperphenylalani... | |||||||||||||
Medical condition: Hyperphenylalaninemia due to phenylalanine hydroxylase deficiency. Phenotypes: classic phenylketonuria (PKU), mild PKU (MPK) or mild hyperphenylalaninemia (HPA). | |||||||||||||
|
|||||||||||||
Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-023923-78 | Sponsor Protocol Number: FH-1.3 | Start Date*: 2011-03-30 |
Sponsor Name:Forsight Vision 4, Inc. | ||
Full Title: “ A prospective clinical trial to evaluate the V4 Drug delivery device for long term delivery of Ranibizumab for the Treatment of Choroidal Neovascularization” | ||
Medical condition: Choroidal Neovascularization (CNV) secondary to Age-related Macular Degeneration (AMD) is among the leading causes of blindness in the world. The primary treatment modality is injection of Lucentis... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2004-001589-42 | Sponsor Protocol Number: Tulir 02/01 | Start Date*: 2004-12-25 |
Sponsor Name:NeuroBiotec GmbH | ||
Full Title: Transdermal lisuride: Phase II/III study (efficacy and tolerance) of transdermal lisuride (patches) in patients with Restless Legs Syndrome (RLS) | ||
Medical condition: Patients suffering from Restless Legs Syndrome (RLS) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2007-003858-29 | Sponsor Protocol Number: CISCA-Studie“ Protokollversion 4.0 | Start Date*: 2008-02-27 |
Sponsor Name:Universitätsklinikum Tübingen, Medizinische Klinik I | ||
Full Title: Prospektive multizentrische Phase-III-Studie zur ambulanten Therapie mit Capecitabin versus Cisplatin plus Capecitabin beim fortgeschrittenen Adenokarzinom der Gallenblase und Gallenwege („CISCA-St... | ||
Medical condition: Karzinome der Gallenblase, Karzinome der extrahepatischen Gallengänge | ||
Disease: | ||
Population Age: | Gender: Male, Female | |
Trial protocol: AT (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2021-005602-10 | Sponsor Protocol Number: 1.1 | Start Date*: 2022-01-20 |
Sponsor Name:Verein zur Förderung der Forschung auf dem Gebiet der Arteriosklerose, Thrombose und vaskulären Biologie (ATVB) | ||
Full Title: POESIA Study: Pleiotropic effects of PCSK 9 inhibition and bempedoic acid - Changes in Platelet Function and Inflammation Markers | ||
Medical condition: platelet activity and inflammation markers in patients with coronary artery disease | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2022-000660-22 | Sponsor Protocol Number: Benzylbenzoat-Permethrin-5020 | Start Date*: 2022-06-14 |
Sponsor Name:Landeskrankenhaus Salzburg | ||
Full Title: Investigation to assess the efficacy of topical benzyl benzoate 10/25% emulsion versus permethrin 5% creme for scabies treatment | ||
Medical condition: Scabies | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2014-004961-26 | Sponsor Protocol Number: 12-009 | Start Date*: 2015-12-15 | |||||||||||||||||||||||||||||||||||||||||
Sponsor Name:McMaster University | |||||||||||||||||||||||||||||||||||||||||||
Full Title: Prophylactic Antibiotic Regimens in Tumor Surgery (PARITY): A Multi-Center Randomized Controlled Study Comparing Alternative Antibiotic Regimens in Patients Undergoing Tumor Resections with Endopro... | |||||||||||||||||||||||||||||||||||||||||||
Medical condition: ? Patients with a primary bone malignancy or soft-tissue sarcoma that has invaded a lower extremity bone that are undergoing surgical treatment to resect the tumor and functionally reconstruct the ... | |||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||
Trial protocol: ES (Ongoing) AT (Completed) | |||||||||||||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-000860-28 | Sponsor Protocol Number: 02CLLIII | Start Date*: 2004-12-02 | |||||||||||
Sponsor Name:ribosepharm GmbH | |||||||||||||
Full Title: PHASE III, OPEN-LABEL, RANDOMIZED, MULTICENTER EFFICACY AND SAFETY STUDY OF BENDAMUSTINE HYDROCHLORIDE VERSUS CHLORAMBUCIL IN TREATMENT-NAÏVE PATIENTS WITH (BINET STAGE B/C) B-CLL REQUIRING THERAPY | |||||||||||||
Medical condition: Hematopoietic insufficiency with non-hemolysis-induced Hb <10 g/dL Thrombocytopenia <100x109/L (equivalent to Binet stage C) B symptoms Rapidly progressive disease (such as rapid lymphoma growth, r... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-003399-30 | Sponsor Protocol Number: I8B-MC-ITSG | Start Date*: 2018-10-24 | |||||||||||
Sponsor Name:Eli Lilly and Company | |||||||||||||
Full Title: A Prospective, Randomized, Double-Blind Comparison of LY900014 and Fiasp®, Both in Combination with Basal Insulin in Adults with Type 1 Diabetes, PRONTO-Compare | |||||||||||||
Medical condition: Diabetes Mellitus, Type 1 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Prematurely Ended) ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-002264-27 | Sponsor Protocol Number: ENGOT-ov54/Swiss-GO-2/MATAO | Start Date*: 2021-03-17 |
Sponsor Name:Swiss GO Trial Group | ||
Full Title: MAintenance Therapy with Aromatase inhibitor in epithelial Ovarian cancer: a randomized double-blinded placebo-controlled multi-center phase III Trial (ENGOT-ov54/Swiss-GO-2/MATAO) including LOGOS ... | ||
Medical condition: Patients with low and high grade serous and endometrioid ovarian cancer patients. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: AT (Trial now transitioned) DE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2019-000616-28 | Sponsor Protocol Number: AGMT_DISCOVER | Start Date*: 2019-07-16 | |||||||||||
Sponsor Name:AGMT gGmbH | |||||||||||||
Full Title: Multicenter, randomized, double-blind, placebo-controlled, phase III clinical trial to investigate the efficacy and safety of Dronabinol in the Improvement of ChemOthErapy-induced and tumor-Related... | |||||||||||||
Medical condition: Advanced pancreatic (locally advanced, inoperable or metastatic) cancer during first-line chemotherapy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) DE (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-002460-13 | Sponsor Protocol Number: VITDALIZE | Start Date*: 2017-01-03 |
Sponsor Name:Medical University of Graz | ||
Full Title: Effect of high-dose vitamin D3 on 28-day mortality in adult critically ill patients with severe vitamin D deficiency: a multicenter, placebo-controlled double-blind phase III RCT | ||
Medical condition: Adult critically ill patients with severe vitamin D deficiency | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Trial now transitioned) GB (GB - no longer in EU/EEA) | ||
Trial results: (No results available) |
EudraCT Number: 2017-002163-17 | Sponsor Protocol Number: 15-138 | Start Date*: 2018-10-25 |
Sponsor Name:RWTH Aachen University represented by the Center for Translational & Clinical Research Aachen (CTC-A) | ||
Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTRE STUDY OF THE EFFICACY AND SAFETY OF NICOTINAMIDE IN PATIENTS WITH FRIEDREICHS ATAXIA. | ||
Medical condition: Friedreich Ataxia | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: DE (Prematurely Ended) AT (Prematurely Ended) GB (GB - no longer in EU/EEA) ES (Ongoing) | ||
Trial results: View results |
EudraCT Number: 2017-000381-29 | Sponsor Protocol Number: SCY-078-301 | Start Date*: 2017-07-17 |
Sponsor Name:SCYNEXIS, Inc. | ||
Full Title: Open-Label Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients with Fungal Diseases that are Refractory to, Resistant to or Intolerant of Standard Antifungal Treatment (FURI) | ||
Medical condition: Patients > 18 years of age with a documented invasive and/or severe fungal disease that has been intolerant, resistant or refractory (rIFI) to Standard of Care (SoC) antifungal treatment. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) AT (Completed) ES (Ongoing) GB (GB - no longer in EU/EEA) | ||
Trial results: View results |
EudraCT Number: 2020-000605-84 | Sponsor Protocol Number: XPORT-DLBCL-030 | Start Date*: 2020-09-16 | ||||||||||||||||
Sponsor Name:Karyopharm Therapeutics Inc. | ||||||||||||||||||
Full Title: A Phase 2/3, Multicenter Randomized Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (RR DL... | ||||||||||||||||||
Medical condition: Relapsed/Refractory Diffuse Large B-Cell Lymphoma (RR DLBCL) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: AT (Ongoing) FR (Ongoing) IT (Trial now transitioned) GR (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-005106-23 | Sponsor Protocol Number: ALLSCT06BFMi | Start Date*: 2007-06-27 | |||||||||||
Sponsor Name:St. Anna Kinderkrebsforschung | |||||||||||||
Full Title: Allogenic stem cell transplantation in children and adolescents with acute lymphoblastic leukaemia | |||||||||||||
Medical condition: very high risk acute lymphoblastic leukaemia in children and adolescents with indicaton for allogenic hematopoetic stem cell transplantation | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) IT (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-019497-32 | Sponsor Protocol Number: PGL09-027 | Start Date*: 2010-11-09 | |||||||||||
Sponsor Name:PregLem S.A. | |||||||||||||
Full Title: A Phase III, multicentre, clinical study investigating the efficacy and safety of three successive periods of 3-month open-label PGL4001 treatment, each followed by ten days of double-blind treatme... | |||||||||||||
Medical condition: Uterine myomas are benign, monoclonal, hormone-sensitive, smooth muscle tumours of the uterus. They are the most common tumour of the female reproductive tract in pre-menopausal women and mostly as... | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: BE (Completed) PL (Completed) AT (Completed) ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-001465-33 | Sponsor Protocol Number: PGL11-024 | Start Date*: 2012-07-09 | |||||||||||
Sponsor Name:PregLem S.A. | |||||||||||||
Full Title: A Phase III, multicentre, extension study investigating the efficacy and safety of repeated intermittent 3-month courses of open-label administration of ulipristal acetate, in subjects with symp... | |||||||||||||
Medical condition: Uterine myomas are benign, monoclonal, hormone-sensitive, smooth muscle tumours of the uterus. They are the most common tumour of the female reproductive tract in pre-menopausal women and mostly a... | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: BE (Completed) AT (Completed) ES (Ongoing) PL (Completed) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
